Analysts have been eager to weigh in on the Healthcare sector with new ratings on Oncternal Therapeutics (ONCT – Research Report) and 180 Life Sciences (ATNF – Research Report). Oncternal Therapeutics (ONCT) In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Oncternal Therapeutics, with a price target of $3.50. The company's shares closed last Wednesday at $1.12, close to its 52-week low of $0.69. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-oncternal-therapeutics-onct-and-180-life-sciences-atnf?utm_source=advfn.com&utm_medium=referral